Clarity Pharmaceuticals Ltd (CLRPF)
OTC Markets OTCPK · USD · Healthcare · Biotechnology
$1.11 (-0.90%) as of
Key statistics
- Market cap
- 412.25M
- EPS (TTM)
- -0.2000
- Dividend yield
- 0.00%
- 52-week range
- 1.1050 – 3.4480
- Beta
- 1.18
- Revenue (TTM)
- 10.53M
- Profit margin
- 0.00%
- Volume
- 1.00k
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Sydney, NSW, Australia
- Employees
- 100
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.